Institute of Medicine, Chung Shan Medical University, No. 110, Sec. 1, Jianguo, N. Rd, Taichung, 40201, Taiwan.
Osteoporos Int. 2011 Feb;22(2):577-85. doi: 10.1007/s00198-010-1327-x. Epub 2010 Aug 24.
In this pilot study, we demonstrated that women with osteopontin (OPN) over-expression show less resistance to postmenopausal osteoporosis than women with normal OPN levels. We hypothesized that the levels of plasma OPN could be used as a treatment indicator for intermittent parathyroid hormone (PTH)-treated menopausal osteoporosis. We demonstrated that plasma OPN levels could be used as a biomarker for early treatment response.
Animal studies indicate that OPN-deficient mice are resistant to ovariectomy induced osteoporosis. Our pilot study also demonstrated women with OPN over expression may show less resistance to postmenopausal osteoporosis. The role of plasma OPN in PTH1-34-treated osteoporosis remains unclear.
From September 2005 to September 2006, 31 menopausal women over 45 years of age with severe osteoporosis were enrolled in our study. Subjects were treated with PTH1-34 subcutaneously at a dose of 20 μg/day. Plasma OPN levels and BMD of the lumbar spine and hip were measured using ELISA and dual-energy X-ray absorptiometry at baseline, 3, 6, and 9 months. Response to the treatment was assessed by the sequential change in bone mineral density and OPN expression using a general linear mixed model.
The plasma OPN decreased sequentially and significantly throughout the 9-month treatment course from 20.75 ± 5.36 to 11.2 ± 4.37 ng/ml (p < 0.001). The sequential improvement in the T-score and Z-score was significant in the lumbar spine but not in the hip area. In the lumbar spine, when the plasma OPN decreased by 1 ng/ml the T-score increased by 0.0406 and the Z-score increased by 0.0572 of lumbar spine.
OPN levels are related to the anabolic effect of PTH in human postmenopausal osteoporosis. Plasma OPN levels could be used as a biomarker for early treatment response.
本研究旨在探讨骨桥蛋白(OPN)水平与绝经后骨质疏松症的关系。方法:对 31 例绝经后骨质疏松症患者进行为期 9 个月的皮下注射甲状旁腺激素(PTH)治疗,检测患者治疗前后血清 OPN 水平及腰椎和髋部骨密度的变化。结果:血清 OPN 水平在治疗后逐渐下降,与治疗前相比差异有统计学意义(P<0.001)。腰椎 T 评分和 Z 评分在治疗后逐渐升高,与治疗前相比差异有统计学意义(P<0.001)。结论:血清 OPN 水平与绝经后骨质疏松症患者的骨密度呈正相关,可作为治疗反应的早期预测指标。